Moderna believes messenger RNA, or mRNA, is the “software of life.”

Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.

Given its essential role, they believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

They are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. 

Since their founding in 2010, they have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Their pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and they have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, they have numerous discovery programs advancing toward development.